Canadian Approval for Eir-051
EirGen Pharma is pleased to announce today that Health Canada have given licence approval to the company’s breast cancer treatment Eir-051. According to co-founder Patsy Carney, “this product approval within 8 months of dossier submission to Health Canada is an indication of the quality of the scientific data generated and represents a significant milestone in EirGen Pharma’s strategy to commercialise its product portfolio internationally”.
EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.